Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR201 in Relapsed or Refractory DLBCL
NCT06517004Phase 1Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of jwcar201 in diffuse large B-cell lymphoma (DLBCL), sponsored by Fudan University. Primary endpoints: Rate of dose-limiting toxicities at 28 days and Adverse Events and Serious Adverse Events at 24 months. Started Jul 2024; status: recruiting.
02
Drugs
jwcar201
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06517004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517004.